Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.11 per share when it actually produced a loss of $0.03, delivering a surprise of 72.73%.Over the last four quar ...

Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual Film in March 2024Reaffirms anticipated FDA decision on Libervant™ (diazepam) Buccal Film application in April 2024Provides full year 2024 financial guidanceHosts investment community conference call on March 6, 2024 WARREN, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ C ...

Core Viewpoint - The average brokerage recommendation (ABR) for Aquestive Therapeutics (AQST) is 1.00, indicating a Strong Buy based on recommendations from four brokerage firms, all of which are Strong Buy [1][2]. Group 1: Brokerage Recommendations - The ABR of 1.00 is derived from four Strong Buy recommendations, representing 100% of the total recommendations [1]. - Despite the positive ABR, studies indicate that brokerage recommendations may not effectively guide investors in selecting stocks with the highest price increase potential [2][5]. - Brokerage firms often exhibit a strong positive bias in their ratings due to vested interests, leading to a disproportionate number of Strong Buy recommendations compared to Strong Sell [2][3]. Group 2: Zacks Rank vs. ABR - The Zacks Rank is a quantitative model based on earnings estimate revisions, providing a more reliable indicator of near-term stock performance compared to the ABR [4][5]. - The Zacks Rank is displayed in whole numbers (1 to 5) and maintains a balance among the ranks, while the ABR is calculated based on brokerage recommendations and can include decimals [4][5]. - The Zacks Rank is updated more frequently, reflecting timely changes in earnings estimates, unlike the ABR which may not be current [6]. Group 3: Current Earnings Estimates for AQST - The Zacks Consensus Estimate for Aquestive Therapeutics remains unchanged at -$0.07 for the current year, suggesting steady analyst views on the company's earnings prospects [7]. - The unchanged consensus estimate has resulted in a Zacks Rank of 3 (Hold) for Aquestive Therapeutics, indicating a cautious approach despite the Buy-equivalent ABR [7].

In the latest market close, Aquestive Therapeutics (AQST) reached $3.67, with a +0.55% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.52% for the day. Meanwhile, the Dow experienced a rise of 0.12%, and the technology-dominated Nasdaq saw an increase of 0.9%.The specialty pharmaceutical company's stock has climbed by 52.72% in the past month, exceeding the Medical sector's gain of 5.15% and the S&P 500's gain of 3.85%.The investment community will be clos ...

Aquestive Therapeutics (AQST) is expected to report fourth-quarter and full-year 2023 results later this month or early next month. In the last reported quarter, the company beat earnings expectations by 72.73%.Factors to ConsiderAquestive earns royalty revenues from its five out-licensed marketed products that it supplies under license deals with partners. Aquestive is the exclusive manufacturer of these licensed products. Its revenues from these products are expected to have increased in the fourth quarte ...

In the latest trading session, Aquestive Therapeutics (AQST) closed at $2.65, marking a -1.67% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.6%. Meanwhile, the Dow lost 0.17%, and the Nasdaq, a tech-heavy index, lost 0.92%.Shares of the specialty pharmaceutical company have appreciated by 7.37% over the course of the past month, outperforming the Medical sector's gain of 4.52% and the S&P 500's gain of 3.56%.The investment community will be closely monitoring the ...

The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular (IM) injection.Anaphylm candidate, with the potential to be the first and only non-invasive, orally delivered epinephrine product, demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of severe allergic reactions, including anaphylaxis. A Phase 3 pi ...

Aquestive Therapeutics (AQST) closed at $2.68 in the latest trading session, marking a +1.13% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.96%. Elsewhere, the Dow saw an upswing of 0.4%, while the tech-heavy Nasdaq appreciated by 1.3%.Heading into today, shares of the specialty pharmaceutical company had lost 0.19% over the past month, lagging the Medical sector's gain of 1.18% and the S&P 500's gain of 3.69% in that time.The upcoming earnings release of Aquestive ...

Aquestive Therapeutics (AQST) ended the recent trading session at $2.68, demonstrating a +1.52% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.13%, and the Nasdaq, a tech-heavy index, added 0.24%.Shares of the specialty pharmaceutical company have appreciated by 3.13% over the course of the past month, underperforming the Medical sector's gain of 3.52% and the S&P 500's gain of 6.45%.Market participants will be cl ...